Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MRE0094 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| MRE0094 | DRUG | - |
Inclusion Criteria: Participants included in the study must: * Have type 1 or type 2 diabetes mellitus. * Have problems with the nerves in their feet. * Have an ulcer on the bottom surface of their foot that has been present for 3 weeks or more and is of sufficient size to qualify for the study. *...
MRE0094 is an investigational small molecule being studied for the treatment of diabetic foot ulcers, specifically chronic, neuropathic diabetic foot ulcers. It is being developed by Pfizer, Inc. and is intended to address complications of diabetes, including foot ulcers that are difficult to heal.
MRE0094 is being developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in clinical development for diabetic foot ulcers.
MRE0094 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with diabetic foot ulcers.
MRE0094 has one completed Phase 2 clinical trial, identified by the National Clinical Trial number NCT00312364. The trial, titled 'Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers,' enrolled 322 participants in the United States and was a randomized, double-blind study.
MRE0094 is the primary name used for this investigational drug in clinical trials. No alternative names have been reported in the available clinical trial information, so it is not known to be the same as any other marketed or investigational drug.